The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
about
Molecular recognition of CCR5 by an HIV-1 gp120 V3 loopComprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesStructure determination of an anti-HIV-1 Fab 447-52D–peptide complex from an epitaxially twinned data setStructural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based ImmunogensHuman Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic StructureThe synthetic peptide derived from the NH2-terminal extracellular region of an orphan G protein-coupled receptor, GPR1, preferentially inhibits infection of X4 HIV-1Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodiesHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesAntigenic and 3D structural characterization of soluble X4 and hybrid X4-R5 HIV-1 Env trimersVisualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.Dual spatial folds and different local structures of the HIV-1 immunogenic crown in various virus isolates.Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopesConformational preferences of the HIV-1 principal neutralizing determinant.Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusingInternational network for comparison of HIV neutralization assays: the NeutNet report.A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoproteinAnalysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-FcStructure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodiesIdentification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants.Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247.Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting VirusesAntibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heteroloFunctional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary virusesVaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.HIV-1 vaccines and co-infection.
P2860
Q21559473-99276CD7-A194-47F7-89C0-8DEFCA280426Q24561905-FCA21840-4B65-49F2-AA64-3BF76EB40B89Q27489000-02C2B31A-B447-4128-AC51-9E48280F03D9Q27650903-80C7FFB9-02E8-4BB1-ADD3-D1797FB71CE5Q27658173-E6DC2911-B33C-4C51-90E0-440F5B0429FEQ27676155-A8F875D0-DCAF-42FB-B787-8BC830C04143Q28253096-A3FC377D-F2DD-4367-A89A-B457C15AFD1BQ28477253-832B450E-33BC-45E5-BA7F-B02D9C40D74BQ29619015-1147C004-1473-4B41-981E-3EE577033859Q30580101-FBA56925-9314-4590-AE75-E941F840A95DQ30603475-092C0B74-7FFD-4982-837C-D1D6E17FC364Q30952700-5BEB0C1A-BAFC-45E4-A3CE-31C7723F7BA1Q30994182-83403430-7C6F-4EAF-836D-3C0271E2883CQ31010762-0281005B-F17E-4C6E-B758-D52A01FA33A7Q33392865-479EF77D-C2C0-4DCC-AA9A-C311C5E9DB92Q33410826-6B911888-4829-48DD-9195-810C283015C6Q33522232-AB6BE172-87D2-4E3C-BB43-ED4E81FEA9B8Q33526340-29B489B5-DBB6-4828-AC7B-C9D43F19D99EQ33788810-2CFCF9E6-47EE-4434-A5C2-DC57C14BC106Q33984231-7E360E63-81E4-4EB5-82FF-6E17ECCC06C7Q34128200-105512EA-9CCF-4DA4-97FB-DD54C2FA3290Q34204047-C3E5FB6E-A2A5-46F0-8ADC-B5CB2C3FB42AQ34392963-446DCDC4-71C9-4C85-AB9B-2D3FD40716D5Q34406977-C8AD88CA-781B-4747-8911-C91D79C6B3D5Q34499013-0F28BB75-B394-4C12-A2BD-9FE351DAF09AQ34543052-44D09A0B-C885-4307-BB1A-62A51249D427Q34648079-F19F98B7-7F9E-44D6-AD86-002FAB7ED096Q34648342-ECBFCE4B-5AD3-4053-8091-E516B581D754Q34717113-3F13CA57-A88A-4D97-ABF8-295C6062926DQ34717733-398F2770-E959-4637-B5F2-5D208A033780Q34847834-D717EBC0-FD0F-4947-80B7-82D212E12052Q34948847-7914759F-19E1-45C9-9D1B-D7ACCF7C2AD7Q35024202-0C62A87B-2974-4044-8566-E5270C1B5F19Q35168642-8AA124D4-50A7-4672-90E4-B3E7529C2C6EQ35569049-0DE153B5-89A5-41B2-876D-B85CEEFFBF31Q35636394-FDDCD862-F89B-40DE-89B5-0276FE587F71Q35706462-46F1FD90-3D49-4D2A-BB49-03B980E1E1B6Q35785244-815DD153-7A0D-4BA0-B32C-02408350D1CBQ35857683-94F53163-D58A-4F71-84D3-184A84CCBC3EQ35873784-0965BA73-71D2-4A16-8049-F3F4D54BC621
P2860
The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The v3 loop is accessible on t ...... s as a neutralization epitope.
@en
type
label
The v3 loop is accessible on t ...... s as a neutralization epitope.
@en
prefLabel
The v3 loop is accessible on t ...... s as a neutralization epitope.
@en
P2093
P2860
P1433
P1476
The v3 loop is accessible on t ...... es as a neutralization epitope
@en
P2093
Abraham Pinter
Arthur Nadas
Barbara Volsky
Christopher A Anyangwe
Constance Williams
John R Mascola
Kathy Revesz
Mark K Louder
Phillipe N Nyambi
Samuel C Kayman
P2860
P304
P356
10.1128/JVI.78.5.2394-2404.2004
P407
P577
2004-03-01T00:00:00Z